​

Incyte (INCY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

INCY Stock Forecast

Incyte (INCY) stock forecast, based on 44 Wall Street analysts, predicts a 12-month average price target of $108.90, with a high of $135.00 and a low of $84.00. This represents a 15.06% increase from the last price of $94.65.

$50 $67 $84 $101 $118 $135 High: $135 Avg: $108.9 Low: $84 Last Closed Price: $94.65

INCY Stock Rating

Incyte stock's rating consensus is Buy, based on 44 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 24 Buy (54.55%), 18 Hold (40.91%), 2 Sell (4.55%), and 0 Strong Sell (0.00%).

Buy
Total 44 0 2 18 24 Strong Sell Sell Hold Buy Strong Buy

INCY Price Target Upside V Benchmarks

TypeNameUpside
StockIncyte15.06%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-621
Avg Price Target-$116.67$103.57
Last Closing Price$94.65$94.65$94.65
Upside/Downside-23.26%9.42%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2629121125
Mar, 26210122-26
Feb, 2629122-25
Jan, 26210112-25
Dec, 2529122-25
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 18, 2026Barclays$117.00$101.1615.66%23.61%
Feb 11, 2026Morgan Stanley$102.00$98.453.61%7.77%
Feb 11, 2026Stephen WilleyStifel Nicolaus$120.00$100.0519.94%26.78%
Feb 06, 2026Allison BratzelPiper Sandler$110.00$102.767.05%16.22%
Feb 05, 2026H.C. Wainwright$135.00$102.6031.58%42.63%
Feb 04, 2026Barclays$116.00$100.9214.94%22.56%
Jan 20, 2026Wells Fargo$107.00$106.210.74%13.05%
Jan 08, 2026Goldman Sachs$90.00$110.57-18.60%-4.91%
Jan 05, 2026Stephen WilleyStifel Nicolaus$119.00$101.7916.91%25.73%
Dec 24, 2025Srikripa DevarakondaTruist Financial$103.00$100.912.07%8.82%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 24, 2026BarclaysOverweightOverweighthold
Feb 06, 2026Piper SandlerOverweightOverweighthold
Feb 05, 2026H.C. WainwrightBuyinitialise
Feb 04, 2026BarclaysOverweightOverweighthold
Jan 13, 2026Cowen & Co.BuyBuyhold
Jan 08, 2026Goldman SachsNeutralNeutralhold
Dec 08, 2025Wells FargoOverweightOverweighthold
Nov 24, 2025BarclaysOverweightOverweighthold
Nov 04, 2025Piper SandlerOverweightOverweighthold
Oct 29, 2025RBC CapitalSector PerformSector Performhold

Financial Forecast

EPS Forecast

$0 $3 $6 $9 $12 $15 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.30$1.53$2.67$0.16$6.59---
Avg Forecast$2.58$1.76$3.60$1.26$5.90$7.18$8.78$10.69
High Forecast$2.76$1.86$3.70$1.53$6.91$9.31$11.60$11.43
Low Forecast$2.47$1.65$3.50$1.01$4.97$5.47$6.71$10.10
Surprise %66.67%-13.07%-25.83%-87.30%11.69%---

Revenue Forecast

$3B $3B $4B $5B $6B $7B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.99B$3.39B$3.70B$4.24B$5.14B---
Avg Forecast$2.92B$3.34B$3.69B$4.20B$4.64B$5.05B$5.46B$5.94B
High Forecast$3.08B$3.49B$3.73B$4.25B$4.89B$5.10B$5.52B$6.26B
Low Forecast$2.83B$3.18B$3.66B$4.13B$4.45B$5.01B$5.40B$5.70B
Surprise %2.12%1.69%0.18%0.87%10.90%---

Net Income Forecast

$0 $600M $1B $2B $2B $3B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$948.58M$340.66M$597.60M$32.62M$1.29B---
Avg Forecast$1.33B$1.45B$597.60M$287.16M$1.34B$1.26B$1.52B$2.41B
High Forecast$1.60B$1.74B$717.12M$345.89M$1.56B$2.10B$2.62B$2.58B
Low Forecast$1.07B$1.16B$478.08M$228.42M$1.12B$1.24B$1.52B$2.28B
Surprise %-28.88%-76.49%--88.64%-4.12%---

INCY Forecast FAQ

Is Incyte stock a buy?

Incyte stock has a consensus rating of Buy, based on 44 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 24 Buy, 18 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Incyte is a favorable investment for most analysts.

What is Incyte's price target?

Incyte's price target, set by 44 Wall Street analysts, averages $108.9 over the next 12 months. The price target range spans from $84 at the low end to $135 at the high end, suggesting a potential 15.06% change from the previous closing price of $94.65.

How does Incyte stock forecast compare to its benchmarks?

Incyte's stock forecast shows a 15.06% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Incyte over the past three months?

  • April 2026: 8.00% Strong Buy, 36.00% Buy, 48.00% Hold, 4.00% Sell, 4.00% Strong Sell.
  • March 2026: 7.69% Strong Buy, 38.46% Buy, 46.15% Hold, 7.69% Sell, 0% Strong Sell.
  • February 2026: 8.00% Strong Buy, 36.00% Buy, 48.00% Hold, 8.00% Sell, 0% Strong Sell.

What is Incyte’s EPS forecast?

Incyte's average annual EPS forecast for its fiscal year ending in December 2026 is $7.18, marking a 8.95% increase from the reported $6.59 in 2025. Estimates for the following years are $8.78 in 2027, and $10.69 in 2028.

What is Incyte’s revenue forecast?

Incyte's average annual revenue forecast for its fiscal year ending in December 2026 is $5.05B, reflecting a -1.69% decrease from the reported $5.14B in 2025. The forecast for 2027 is $5.46B, and $5.94B for 2028.

What is Incyte’s net income forecast?

Incyte's net income forecast for the fiscal year ending in December 2026 stands at $1.26B, representing a -2.14% decrease from the reported $1.29B in 2025. Projections indicate $1.52B in 2027, and $2.41B in 2028.